/Biogen%20Inc%20magnified-by%20Casimiro%20PT%20via%20Shutterstock.jpg)
Valued at a market cap of $22.1 billion, Biogen Inc. (BIIB) is a top biotechnology company. Headquartered in Cambridge, Massachusetts, it specializes in the discovery, development, and delivery of therapies for neurological, neurodegenerative, and rare diseases. Founded in 1978, Biogen has built a strong presence in neuroscience, focusing on addressing unmet medical needs in conditions such as multiple sclerosis (MS), spinal muscular atrophy (SMA), and Alzheimer’s disease.
The biotech titan is scheduled to announce its fiscal Q3 earnings for 2025 before the market opens on Thursday, Oct. 30. Before this event, analysts project the company to report a profit of $3.94 per share, down 3.4% from $4.08 per share in the year-ago quarter. The company has surpassed Wall Street’s bottom-line estimates in three of the last four quarters, while missing on another occasion.